A carregar...
Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
AIMS: To compare the once‐weekly glucagon‐like peptide‐1 (GLP‐1) receptor dulaglutide with the dipeptidyl peptidase‐4 (DPP‐4) inhibitor sitagliptin after 104 weeks of treatment. METHODS: This AWARD‐5 study was a multicentre, double‐blind trial that randomized participants to dulaglutide (1.5 or 0.75...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5008205/ https://ncbi.nlm.nih.gov/pubmed/25912221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12479 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|